Phosducin is a 33-kDa cytosolic regulator of G-protein-mediated signaling that has previously been thought to be specific for retina and pineal gland. In this study, we show widespread tissue distribution of phosducin by the amplification of its cDNA and the detection of two different transcripts in Northern analyses in liver, lung, heart, brain, and retina. On the protein level, phosducin could be detected in 12 bovine tissues by immune precipitation and subsequent Western analysis using anti-phosducin antibodies generated in two different species. Masking of phosducin in direct Western blots appears to explain the failure to detect phosducin in earlier studies. The concentration of phosducin in bovine brain was calculated in the range of 10 pmol/mg total cytosolic protein (-1I,uM), whereas in the other tissues, it was slightly less. In these concentrations, phosducin inhibited receptor-stimulated adenylyl cyclase activity in cell membranes by about 50%. Taken together, our results indicate that phosducin is a ubiquitous regulator of G-protein function.
mediated signal transduction by high-affinity binding to Gf3y and may, thereby, regulate the number of f3y subunits available to interact with the Ga subunits. Phosducin has been shown to inhibit the intrinsic GTPase activity of Gs, and inhibitory and "other" G proteins (G1 and Go, respectively) equally well (12) . Similarly, it has been shown to reduce the activity of Gt (13) . Furthermore, it impairs the Gf3y-mediated enhancement of 032-adrenergic receptor phosphorylation by the f3-adrenergic receptor kinase (14) . It has been suggested that phosducin traps G-protein fBy subunits and thereby impairs activation of the receptor (13) . Phosducin can be phosphorylated by protein kinase A (7) , and upon phosphorylation, its affinity for Gfy decreases (12) , presumably due to a conformational change enabling the Ga subunits to displace phosducin and to couple effectively to the receptor (15) .
The occurrence of phosducin is generally thought to be limited to retina and pineal gland. Although we have purified phosducin (or a very similar protein) from bovine brain, the possibility of a contamination by pineal tissue was not completely ruled out in these studies (12) . Several attempts to detect phosducin in nonretinal/pineal tissues with specific antibodies have produced negative results (8, (16) (17) (18) . Furthermore, phosducin mRNA has been shown to be specific for retina and pineal gland (17) . More recently, the cDNA of a phosducin-like protein has been identified in brain and other organs (19) . Like phosducin, phosducin-like protein is also capable of inhibiting Go GTPase. This raises the possibility that, like many other proteins in the retinal versus hormonal signaling systems, phosducin might be specific for the retina, whereas phosducin-like protein might be its peripheral counterpart.
This study was undertaken to test this hypothesis and to investigate the presence of phosducin and its mRNA in nonretinal/pineal tissues. We demonstrate that it occurs in a wide variety of bovine tissues at the mRNA level and protein level, respectively, and that its concentration in these tissues is sufficient to act as a G-protein regulator.
MATERIALS AND METHODS
RNA Isolation and Northern Blot Analysis. Total RNA was isolated from fresh bovine tissues according to ref. 20 . poly(A)+ RNA was prepared using the mRNA Purification Kit (Pharmacia). RNA was separated on formaldehyde gels, subsequently transferred to nylon membranes (Qiagen, Chatsworth, CA) by downward alcaline capillary transfer (21) , and bound to the membrane by heating to 100°C for 20 min. Single-stranded DNA probes were prepared in two steps. First, the respective region was amplified in a "standard" PCR. The resulting double-stranded DNA fragment was subsequently used as a template in a second, asymmetric PCR that included only the 3' primer. Digoxigenin-11-dUTP (20 ,uM The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 
The positions of the corresponding sequences are numbered according to the published phosducin cDNA from bovine retina (7), numbering the transcription start site with 1. Start and stop codons are underlined.
Finally, an extension step of 10 min was added. The PCR products were purified using the QIAEX Gel Extraction Kit (Qiagen), cloned using the SURE Clone Ligation Kit (Pharmacia) and transformed into Escherichia coli according to Chung and coworkers (22) . The plasmids were isolated with Qiagen columns and sequenced on an automated system (Applied Biosystems).
Characterization of the Transcripts. The primer extension experiments for the determination of the 5' ends of the transcripts were essentially done as described (23 Adenylyl Cyclase Assays in A431 Cell Membranes. Human epidermoid carcinoma cells were grown in DMEM supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 0.1 mg/ml streptomycin. Crude membranes were prepared by disruption of the cells with an Ultra-turrax device and centrifugation of the homogenate at 1000 x g for 5 min followed by centrifugation at 50,000 x g for 20 min. The pellet was resuspended in 50 mM Tris HCl, pH 7.4. Adenylyl cyclase activity in these membranes was determined by measuring the conversion of [a-32P]dATP to [32P]cAMP as described (26) . Recombinant phosducin, prepared as described (12) , was present in these assays in the indicated concentrations. Incubations were done at 37°C for 30 min.
RESULTS
Amplification and Sequence Analysis of the Phosducin Coding Sequence. poly(A)+ RNA from bovine liver, lung, heart, brain, and retina was isolated and reverse transcribed into cDNA using an oligo(dT)15 primer to ensure that complete open reading frames were represented with high probability within the resulting cDNA. The entire coding sequence of phosducin was amplified by PCR using the primersphd.seq.2 andphd.rev.2. Aliquots of the reaction mixtures were separated on an agarose gel (Fig. 1) . In all the tissues tested, a single PCR product of about 740 bp could be detected, which fits exactly to the length of the published phosducin open reading frames (7, 9, 16, 17, 27, 28) .
After subcloning, sequencing of the PCR products using the primers phd.seq.2, phd.seq.3, phd.rev.2, and phd.rev.3 gave identical sequences, which were essentially the same as described earlier (7, 9, 16, 17, 27, 28) . Four silent point mutations could be identified: at position 162 TCC for TCT (Ser), at position 531 GCC for GCG (Ala), at position 633 GAG for GAA (Glu), and at position 679 TTA for CTA (Leu). At position 84 we found GAT (Asp), which has also been reported by Lee and coworkers (7), Craft and coworkers (9) , and Kuo and coworkers (17) , whereas Abe and coworkers (16, 27, 28) found a GAC (Asp). At position 131 CAC (His) could unambiguously be identified in agreement with three other studies (7, 9, 17) , whereas Abe and coworkers (16, 27, 28) found CCC (Pro). In an earlier report, both nucleotides were found at this position (12 Amplification of the phosducin coding sequence. Phosducin cDNA was amplified from cDNA of bovine liver, lung, heart, brain, and retina. Aliquots (10 ,u) of the reaction mixtures were separated on an agarose gel. The length of the PCR product, which corresponds to that of the published coding sequences (7, 9, 16, 17, 27, 28) , is indicated.
Northern Blot Analysis. Total RNA was isolated by the acid guanidinium thiocyanate-phenol-chloroform extraction method (20) , and poly(A)+ RNA was purified by oligo(dT)-cellulose affinity chromatography. The preparations were analyzed in Northern blots with a digoxigenin-labeled probe covering the entire coding region of phosducin to ensure high binding specificity. Use of 15 ,ug of poly(A)+ RNA per lane revealed the existence of two transcripts of about 1300 nt and 900 nt in all tissues studied (Fig. 2) . The larger transcript corresponds to the length of the published cDNA of bovine retinal phosducin (7) but was only one-fifth of the 900-nt transcript. The presence of a second phosducin-mRNA suggests alternative splicing/polyadenylylation as regulatory mechanisms of phosducin transcription.
Characterization of the Phosducin Transcripts. To define the nature of the two mRNA-species, their 5' and 3' ends were investigated and their sequences were determined. The 5' ends of the transcripts were characterized by primer extension analysis. A fragment of 237 nt could be detected in all tissues (Fig. 3A) . The distance between the 5' end of the primer phd.rev.5 and the adenine residue of the start codon was 138 nt. Therefore, the length of the phosducin 5'UTR was determined to be 99 nt, which is in agreement with the published sequence (7). Because no additional fragment could be identified, the two transcripts seem to have identical 5'UTRs. Sequence analysis of the corresponding 237-bp PCR product using the primers phd.seq.1 and phd.rev.5 showed no differences from the sequence described (7) except for two C to A transitions at positions 14 and 20 of the 5'UTR.
The 3' ends of the two transcripts were analyzed by anchored PCR. Two rounds of PCR were performed with different phosducin-specific 5' primers,phd.seq.5 andphd.seq.6, and the same 3' primer, (dT)12ACG. In all five tissues, two fragments of about 600 and 290 bp, respectively, could be identified (Fig.  3B) . Because the distance between phd.seq.6 and the stop codon is 183 bp, the 3'UTRs were about 410 and 100 bp in length, respectively. After amplification and cloning of the (15 ,ug) purified from bovine liver, lung, heart, brain, and retina was separated on a formaldehyde gel and transferred onto a nylon membrane as described. The sizes of the detected transcripts using a digoxigenin-labeled probe covering the entire coding region of phosducin are indicated on the right.
corresponding cDNA fragments, their exact sizes were determined to be 421 and 111 bp, respectively. The two PCR products had identical sequences in the overlapping region, strengthening the hypothesis that the smaller transcript is a 3'-truncated form of the 1300-nt transcript. Four point mutations in comparison to the published sequence (7) were found: at position 87 of the 3'UTR A to C, at positions 403 and 419, respectively, G to T, and at position 420 G to A. The results from the characterization of the two phosducin-specific transcripts are summarized in Fig. 3C .
Immunoprecipitation and Western Blot Analysis. Because we failed to detected phosducin directly in Western analyses in nonretinal tissues (data not shown), a different approach was chosen; phosducin was immunoprecipitated with affinity purified rabbit anti-phosducin antibodies followed by detection in a Western blot analysis using an IgG fraction prepared by caprylic acid precipitation from a goat antiserum generated against purified recombinant phosducin. Using 5 mg of cytosolic protein of nonretinal tissues (stomach, skeletal muscle, spleen, thymus, liver, lung, heart, kidney, adrenal gland, and brain) and 500 ,tg of cytosolic protein of pineal gland and retina, respectively, a signal of 33 kDa could be identified in all tissues; this signal had the same mobility as recombinant phosducin (Fig. 4) Masking of phosducin by other cytosolic prote be the reason for the failure to detect phosdi Western analyses. Increasing amounts of cytF from bovine brain were added to 100 ng of phosducin and subsequently analyzed in a West 5B). This led to a decrease in signal intensity. Wil ,ug of cytosolic protein, the signal completely d
Assuming that brain cytosol is about 10% ii concentration of phosducin can be estimated a wondered whether this concentration would be inhibit G-protein-mediated signaling. Therefor gated the effects of purified recombinant ph model system, the ,3-adrenergic receptor/Gs/ad system of A431 cell membranes. Although t cyclase activity was not significantly altered by I even slightly enhanced), the stimulation induce( renergic receptor agonist (-)isoproterenol was ( concentration-dependent manner (Fig. 6) . A estimated concentration in brain, this inhibition -50%. This result indicates that the concentra ducin present in nonretinal/pineal tissues is sufficient to cause significant inhibition of G-protein function.
DISCUSSION
Phosducin has been isolated and characterized from retina and the evolutionarily related pineal gland in various species. Sequence analyses revealed that it is highly conserved among mammalian organisms (7, 9, 16, 17, 27, 28) . Several approaches -.no 6M bp have been taken so far to investigate the possible presence of > _600bp phosducin in other tissues. As outlined in the Introduction, phosducin mRNA appeared to be specific for retina and pineal -no 290bp gland (17) , and studies with anti-phosducin antibodies (8, 16, 17, 18) suggested that its expression was limited to these two organs. The recent discovery of a ubiquitous phosducin-like protein (19) , which can also inhibit the GTPase function of Go
LTRlk ng (29) , challenged our original hypothesis that phosducin might 421hp have more general functions (12) . Here, we demonstrate the widespread distribution of phosducin by several strategies. First, its coding sequence was amplified from oligo(dT)-primed cDNA of bovine liver, lung, heart, brain, and retina. Abe and coworkers (27) nation and Northern analyses. Apart from some "silent" point ng, heart, brain, mutations, which may be a result of heterogenous tissue loaded on a 6% material in diverse studies, the phosducin sequences were ed DNA of M13 identical in all samples and essentially the same as described (7, er. The size of 9, 16, 17. 27, 28).
Analysis of the
Second, two phosducin-specific transcripts, 1300 and 900 nt, i by PCR using were detected in Northern blots using a probe covering the reverse primer. CYT. [Iig] 200 100 50 500 500 500 --100 500 orders of magnitude higher than the levels of most G-proteincoupled receptors but less than the levels of G proteins, which are in the range of 100 pmol/mg membrane protein (33, 34 ).
Thus, the total level of target proteins exceeds the level of phosducin. However, Lee and coworkers (13) have shown that phosducin has a lag phase of a few seconds before it inhibits the GTPase activity of Gt, and they have concluded that it interacts preferentially with 13'y subunits that are dissociated from the a subunits of activated G proteins. In fact, we observed that phosducin at its calculated cytosolic concentration of -1 ,uM produced very significant inhibition of receptorstimulated cAMP production. In line with this hypothesis, we have recently observed that expression of phosducin at a level of 1 pmol/mg cytosolic protein in cells is sufficient to cause significant dampening of G,-mediated cAMP accumulation (35) . The G-protein fry subunits (GI3y) appear to be the primary target of phosducin (6, 12, 13 Biochemistry: Danner and Lohse 10150 Biochemistry: Danner and Lohse appear to differentiate between various specific ,3 and y subunits (36) . Together with its ubiquitous distribution reported here, these data support our hypothesis that phosducin is a general G-protein regulator.
Taken together, our results indicate that the phosducin gene is expressed in many tissues, in which both its mRNA and the protein itself can be detected. Even though its expression level is lower than that of Gf3y, its primary target, it appears to be sufficient to regulate signaling by activated G proteins. Thus, similarly to GB3y themselves, phosducin is a ubiquitous protein, even though it is more abundant in the retina and pineal gland. This indicates that although some signaling functions in visual and hormonal signaling are performed by very specific proteins, such as rhodopsin and the receptors themselves, others can be exerted by identical proteins in diverse receptor systems.
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